10-Q Filing

TEVA PHARMACEUTICAL INDUSTRIES LTD CIK: 818686 Q3 2018

Filing Information

Form Type	10-Q
Accession Number	`0001193125-18-315734`
Period End Date	20180930
Filing Date	20181101
Fiscal Year	2018
Fiscal Period	Q3
XBRL Instance	teva-20180930.xml

Filing Contents

This filing contains the following financial statements:

Balance Sheet 87 Income Statement 94 Cash Flow Statement 68 Comprehensive Income 34

Balance Sheet 87 line items

Line Item	Tag	Value	Unit	Period
Preferred stock par or stated value per share	`PreferredStockParOrStatedValuePerShare`	0.10	ILS	Point-in-time
Preferred stock par or stated value per share	`PreferredStockParOrStatedValuePerShare`	0.10	ILS	Point-in-time
Preferred stock shares, authorized	`PreferredStockSharesAuthorized`	5.00M	shares	Point-in-time
Preferred stock shares, authorized	`PreferredStockSharesAuthorized`	5.00M	shares	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$1.88B	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$963.00M	USD	Point-in-time
Preferred stock shares, issued	`PreferredStockSharesIssued`	3.70M	shares	Point-in-time
Preferred stock shares, issued	`PreferredStockSharesIssued`	3.70M	shares	Point-in-time
Common stock, par or stated value per share	`CommonStockParOrStatedValuePerShare`	0.10	ILS	Point-in-time
Trade receivables	`AccountsReceivableNetCurrent`	$5.67B	USD	Point-in-time
Trade receivables	`AccountsReceivableNetCurrent`	$7.13B	USD	Point-in-time
Common stock, par or stated value per share	`CommonStockParOrStatedValuePerShare`	0.10	ILS	Point-in-time
Inventories	`InventoryNet`	$4.87B	USD	Point-in-time
Ordinary shares, authorized	`CommonStockSharesAuthorized`	2.50B	shares	Point-in-time
Ordinary shares, authorized	`CommonStockSharesAuthorized`	2.50B	shares	Point-in-time
Inventories	`InventoryNet`	$4.92B	USD	Point-in-time
Ordinary shares, issued	`CommonStockSharesIssued`	1.12B	shares	Point-in-time
Ordinary shares, issued	`CommonStockSharesIssued`	1.12B	shares	Point-in-time
Prepaid expenses	`PrepaidExpenseCurrent`	$911.00M	USD	Point-in-time
Prepaid expenses	`PrepaidExpenseCurrent`	$1.10B	USD	Point-in-time
Treasury shares	`TreasuryStockShares`	106.00M	shares	Point-in-time
Other current assets	`OtherAssetsCurrent`	$483.00M	USD	Point-in-time
Treasury shares	`TreasuryStockShares`	107.00M	shares	Point-in-time
Other current assets	`OtherAssetsCurrent`	$701.00M	USD	Point-in-time
Assets held for sale	`AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent`	$566.00M	USD	Point-in-time
Assets held for sale	`AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent`	$81.00M	USD	Point-in-time
Total current assets	`AssetsCurrent`	$15.38B	USD	Point-in-time
Total current assets	`AssetsCurrent`	$13.88B	USD	Point-in-time
Deferred income taxes	`DeferredTaxAssetsNetNoncurrent`	$427.00M	USD	Point-in-time
Deferred income taxes	`DeferredTaxAssetsNetNoncurrent`	$574.00M	USD	Point-in-time
Other non-current assets	`OtherAssetsNoncurrent`	$932.00M	USD	Point-in-time
Other non-current assets	`OtherAssetsNoncurrent`	$722.00M	USD	Point-in-time
Property, plant and equipment, net	`PropertyPlantAndEquipmentNet`	$7.67B	USD	Point-in-time
Property, plant and equipment, net	`PropertyPlantAndEquipmentNet`	$7.10B	USD	Point-in-time
Identifiable intangible assets, net	`FiniteLivedIntangibleAssetsNet`	$17.64B	USD	Point-in-time
Identifiable intangible assets, net	`FiniteLivedIntangibleAssetsNet`	$15.35B	USD	Point-in-time
Goodwill	`Goodwill`	$28.41B	USD	Point-in-time
Goodwill	`Goodwill`	$27.59B	USD	Point-in-time
Total assets	`Assets`	$65.06B	USD	Point-in-time
Total assets	`Assets`	$70.61B	USD	Point-in-time
Short-term debt	`DebtCurrent`	$3.65B	USD	Point-in-time
Short-term debt	`DebtCurrent`	$2.67B	USD	Point-in-time
Sales reserves and allowances	`SalesReservesAndAllowances`	$6.70B	USD	Point-in-time
Sales reserves and allowances	`SalesReservesAndAllowances`	$7.88B	USD	Point-in-time
Trade payables	`AccountsPayableAndAccruedLiabilitiesCurrent`	$1.63B	USD	Point-in-time
Trade payables	`AccountsPayableAndAccruedLiabilitiesCurrent`	$2.07B	USD	Point-in-time
Employee-related obligations	`EmployeeRelatedLiabilitiesCurrent`	$549.00M	USD	Point-in-time
Employee-related obligations	`EmployeeRelatedLiabilitiesCurrent`	$712.00M	USD	Point-in-time
Accrued expenses	`AccruedExpenses`	$2.23B	USD	Point-in-time
Accrued expenses	`AccruedExpenses`	$3.01B	USD	Point-in-time
Other current liabilities	`OtherLiabilitiesCurrent`	$886.00M	USD	Point-in-time
Other current liabilities	`OtherLiabilitiesCurrent`	$724.00M	USD	Point-in-time
Liabilities held for sale	`LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent`	$38.00M	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$17.92B	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$14.83B	USD	Point-in-time
Deferred income taxes	`DeferredTaxLiabilitiesNoncurrent`	$2.48B	USD	Point-in-time
Deferred income taxes	`DeferredTaxLiabilitiesNoncurrent`	$3.28B	USD	Point-in-time
Other taxes and long-term liabilities	`OtherLiabilitiesNoncurrent`	$1.84B	USD	Point-in-time
Other taxes and long-term liabilities	`OtherLiabilitiesNoncurrent`	$1.80B	USD	Point-in-time
Senior notes and loans	`LongTermNotesAndLoans`	$28.83B	USD	Point-in-time
Senior notes and loans	`LongTermNotesAndLoans`	$26.82B	USD	Point-in-time
Total long-term liabilities	`LiabilitiesNoncurrent`	$33.95B	USD	Point-in-time
Total long-term liabilities	`LiabilitiesNoncurrent`	$31.10B	USD	Point-in-time
Commitments and contingencies, see note 16	`CommitmentsAndContingencies`	-	USD	Point-in-time
Commitments and contingencies, see note 16	`CommitmentsAndContingencies`	-	USD	Point-in-time
Total liabilities	`Liabilities`	$45.93B	USD	Point-in-time
Total liabilities	`Liabilities`	$51.87B	USD	Point-in-time
Preferred shares of NIS 0.10 par value per mandatory convertible preferred share; September 30, 2018 and December 31, 2017: authorized 5.0 million shares; issued 3.7 million shares	`PreferredStockValue`	$3.83B	USD	Point-in-time
Preferred shares of NIS 0.10 par value per mandatory convertible preferred share; September 30, 2018 and December 31, 2017: authorized 5.0 million shares; issued 3.7 million shares	`PreferredStockValue`	$3.63B	USD	Point-in-time
Ordinary shares of NIS 0.10 par value per share; September 30, 2018 and December 31, 2017: authorized 2,495 million shares; issued 1,125 million shares and 1,124 million shares, respectively	`CommonStockValue`	$54.00M	USD	Point-in-time
Ordinary shares of NIS 0.10 par value per share; September 30, 2018 and December 31, 2017: authorized 2,495 million shares; issued 1,125 million shares and 1,124 million shares, respectively	`CommonStockValue`	$54.00M	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapital`	$23.40B	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapital`	$23.48B	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-3.81B	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-3.07B	USD	Point-in-time
Accumulated other comprehensive loss	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$-1.85B	USD	Point-in-time
Accumulated other comprehensive loss	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$-2.33B	USD	Point-in-time
Treasury shares as of September 30, 2018 and December 31, 2017 - 106 million ordinary shares and 107 million ordinary shares, respectively	`TreasuryStockValue`	$4.15B	USD	Point-in-time
Treasury shares as of September 30, 2018 and December 31, 2017 - 106 million ordinary shares and 107 million ordinary shares, respectively	`TreasuryStockValue`	$4.15B	USD	Point-in-time
Stockholders' equity attributable to Teva shareholders	`StockholdersEquity`	$17.73B	USD	Point-in-time
Stockholders' equity attributable to Teva shareholders	`StockholdersEquity`	$17.36B	USD	Point-in-time
Non-controlling interests	`MinorityInterest`	$1.40B	USD	Point-in-time
Non-controlling interests	`MinorityInterest`	$1.39B	USD	Point-in-time
Total equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$19.13B	USD	Point-in-time
Total equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$18.75B	USD	Point-in-time
Total liabilities and equity	`LiabilitiesAndStockholdersEquity`	$65.06B	USD	Point-in-time
Total liabilities and equity	`LiabilitiesAndStockholdersEquity`	$70.61B	USD	Point-in-time

Income Statement 94 line items

Line Item	Tag	Value	Unit	Period
Net revenues	`RevenueFromContractWithCustomerExcludingAssessedTax`	$4.53B	USD	1 Quarter
Net revenues	`RevenueFromContractWithCustomerExcludingAssessedTax`	$16.99B	USD	3 Qtrs
Net revenues	`RevenueFromContractWithCustomerExcludingAssessedTax`	$14.29B	USD	3 Qtrs
Net revenues	`RevenueFromContractWithCustomerExcludingAssessedTax`	$5.62B	USD	1 Quarter
Cost of sales	`CostOfGoodsAndServicesSold`	$2.97B	USD	1 Quarter
Cost of sales	`CostOfGoodsAndServicesSold`	$8.64B	USD	3 Qtrs
Cost of sales	`CostOfGoodsAndServicesSold`	$2.51B	USD	1 Quarter
Cost of sales	`CostOfGoodsAndServicesSold`	$7.87B	USD	3 Qtrs
Gross profit	`GrossProfit`	$6.43B	USD	3 Qtrs
Gross profit	`GrossProfit`	$2.02B	USD	1 Quarter
Gross profit	`GrossProfit`	$2.65B	USD	1 Quarter
Gross profit	`GrossProfit`	$8.34B	USD	3 Qtrs
Research and development expenses	`ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost`	$531.00M	USD	1 Quarter
Research and development expenses	`ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost`	$918.00M	USD	3 Qtrs
Research and development expenses	`ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost`	$1.43B	USD	3 Qtrs
Research and development expenses	`ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost`	$311.00M	USD	1 Quarter
Selling and marketing expenses	`SellingAndMarketingExpense`	$743.00M	USD	1 Quarter
Selling and marketing expenses	`SellingAndMarketingExpense`	$2.22B	USD	3 Qtrs
Selling and marketing expenses	`SellingAndMarketingExpense`	$843.00M	USD	1 Quarter
Selling and marketing expenses	`SellingAndMarketingExpense`	$2.75B	USD	3 Qtrs
General and administrative expenses	`GeneralAndAdministrativeExpense`	$372.00M	USD	1 Quarter
General and administrative expenses	`GeneralAndAdministrativeExpense`	$309.00M	USD	1 Quarter
General and administrative expenses	`GeneralAndAdministrativeExpense`	$954.00M	USD	3 Qtrs
General and administrative expenses	`GeneralAndAdministrativeExpense`	$1.10B	USD	3 Qtrs
Other asset impairments, restructuring and other items	`ImpairmentsRestructuringAndOthers`	$1.21B	USD	3 Qtrs
Other asset impairments, restructuring and other items	`ImpairmentsRestructuringAndOthers`	$658.00M	USD	1 Quarter
Other asset impairments, restructuring and other items	`ImpairmentsRestructuringAndOthers`	$2.08B	USD	3 Qtrs
Other asset impairments, restructuring and other items	`ImpairmentsRestructuringAndOthers`	$550.00M	USD	1 Quarter
Goodwill impairment	`GoodwillImpairmentLoss`	$6.10B	USD	3 Qtrs
Goodwill impairment	`GoodwillImpairmentLoss`	$300.00M	USD	3 Qtrs
Legal settlements and loss contingencies	`LegalSettlementsAndLossContingencies`	$19.00M	USD	1 Quarter
Legal settlements and loss contingencies	`LegalSettlementsAndLossContingencies`	$-20.00M	USD	1 Quarter
Legal settlements and loss contingencies	`LegalSettlementsAndLossContingencies`	$324.00M	USD	3 Qtrs
Legal settlements and loss contingencies	`LegalSettlementsAndLossContingencies`	$-1.24B	USD	3 Qtrs
Other income	`OtherIncome`	$334.00M	USD	3 Qtrs
Other income	`OtherIncome`	$100.00M	USD	3 Qtrs
Other income	`OtherIncome`	$4.00M	USD	1 Quarter
Other income	`OtherIncome`	$35.00M	USD	1 Quarter
Operating income (loss)	`OperatingIncomeLoss`	$16.00M	USD	1 Quarter
Operating income (loss)	`OperatingIncomeLoss`	$378.00M	USD	1 Quarter
Operating income (loss)	`OperatingIncomeLoss`	$-4.47B	USD	3 Qtrs
Operating income (loss)	`OperatingIncomeLoss`	$1.53B	USD	3 Qtrs
Financial expenses, net	`NonoperatingIncomeExpense`	$-259.00M	USD	1 Quarter
Financial expenses, net	`NonoperatingIncomeExpense`	$-229.00M	USD	1 Quarter
Financial expenses, net	`NonoperatingIncomeExpense`	$-704.00M	USD	3 Qtrs
Financial expenses, net	`NonoperatingIncomeExpense`	$-736.00M	USD	3 Qtrs
Income (loss) before income taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments`	$-5.17B	USD	3 Qtrs
Income (loss) before income taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments`	$791.00M	USD	3 Qtrs
Income (loss) before income taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments`	$119.00M	USD	1 Quarter
Income (loss) before income taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments`	$-213.00M	USD	1 Quarter
Tax benefits	`IncomeTaxExpenseBenefit`	$-494.00M	USD	1 Quarter
Tax benefits	`IncomeTaxExpenseBenefit`	$-462.00M	USD	3 Qtrs
Tax benefits	`IncomeTaxExpenseBenefit`	$-26.00M	USD	1 Quarter
Tax benefits	`IncomeTaxExpenseBenefit`	$-56.00M	USD	3 Qtrs
Share in losses of associated companies, net	`IncomeLossFromEquityMethodInvestments`	$-3.00M	USD	1 Quarter
Share in losses of associated companies, net	`IncomeLossFromEquityMethodInvestments`	$-10.00M	USD	3 Qtrs
Share in losses of associated companies, net	`IncomeLossFromEquityMethodInvestments`	$-10.00M	USD	1 Quarter
Share in losses of associated companies, net	`IncomeLossFromEquityMethodInvestments`	$-76.00M	USD	3 Qtrs
Net income (loss)	`ProfitLoss`	$-4.72B	USD	3 Qtrs
Net income (loss)	`ProfitLoss`	$771.00M	USD	3 Qtrs
Net income (loss)	`ProfitLoss`	$-197.00M	USD	1 Quarter
Net income (loss)	`ProfitLoss`	$610.00M	USD	1 Quarter
Net income attributable to non-controlling interests	`NetIncomeLossAttributableToNoncontrollingInterest`	$15.00M	USD	1 Quarter
Net income attributable to non-controlling interests	`NetIncomeLossAttributableToNoncontrollingInterest`	$11.00M	USD	3 Qtrs
Net income attributable to non-controlling interests	`NetIncomeLossAttributableToNoncontrollingInterest`	$11.00M	USD	1 Quarter
Net income attributable to non-controlling interests	`NetIncomeLossAttributableToNoncontrollingInterest`	$35.00M	USD	3 Qtrs
Net income (loss) attributable to Teva	`NetIncomeLoss`	$736.00M	USD	3 Qtrs
Net income (loss) attributable to Teva	`NetIncomeLoss`	$595.00M	USD	1 Quarter
Net income (loss) attributable to Teva	`NetIncomeLoss`	$-208.00M	USD	1 Quarter
Net income (loss) attributable to Teva	`NetIncomeLoss`	$-4.73B	USD	3 Qtrs
Dividends on preferred shares	`PreferredStockDividendsIncomeStatementImpact`	$65.00M	USD	1 Quarter
Dividends on preferred shares	`PreferredStockDividendsIncomeStatementImpact`	$195.00M	USD	3 Qtrs
Dividends on preferred shares	`PreferredStockDividendsIncomeStatementImpact`	$195.00M	USD	3 Qtrs
Dividends on preferred shares	`PreferredStockDividendsIncomeStatementImpact`	$65.00M	USD	1 Quarter
Net income (loss) attributable to ordinary shareholders	`NetIncomeLossAvailableToCommonStockholdersBasic`	$-4.92B	USD	3 Qtrs
Net income (loss) attributable to ordinary shareholders	`NetIncomeLossAvailableToCommonStockholdersBasic`	$-273.00M	USD	1 Quarter
Net income (loss) attributable to ordinary shareholders	`NetIncomeLossAvailableToCommonStockholdersBasic`	$541.00M	USD	3 Qtrs
Net income (loss) attributable to ordinary shareholders	`NetIncomeLossAvailableToCommonStockholdersBasic`	$530.00M	USD	1 Quarter
Basic	`EarningsPerShareBasic`	$-4.85	USD	3 Qtrs
Basic	`EarningsPerShareBasic`	$-0.27	USD	1 Quarter
Basic	`EarningsPerShareBasic`	$0.52	USD	1 Quarter
Basic	`EarningsPerShareBasic`	$0.53	USD	3 Qtrs
Diluted	`EarningsPerShareDiluted`	$-0.27	USD	1 Quarter
Diluted	`EarningsPerShareDiluted`	$0.53	USD	3 Qtrs
Diluted	`EarningsPerShareDiluted`	$0.52	USD	1 Quarter
Diluted	`EarningsPerShareDiluted`	$-4.85	USD	3 Qtrs
Basic	`WeightedAverageNumberOfSharesOutstandingBasic`	1.02B	shares	1 Quarter
Basic	`WeightedAverageNumberOfSharesOutstandingBasic`	1.02B	shares	3 Qtrs
Basic	`WeightedAverageNumberOfSharesOutstandingBasic`	1.02B	shares	3 Qtrs
Basic	`WeightedAverageNumberOfSharesOutstandingBasic`	1.02B	shares	1 Quarter
Diluted	`WeightedAverageNumberOfDilutedSharesOutstanding`	1.02B	shares	3 Qtrs
Diluted	`WeightedAverageNumberOfDilutedSharesOutstanding`	1.02B	shares	1 Quarter
Diluted	`WeightedAverageNumberOfDilutedSharesOutstanding`	1.02B	shares	1 Quarter
Diluted	`WeightedAverageNumberOfDilutedSharesOutstanding`	1.02B	shares	3 Qtrs

Cash Flow Statement 68 line items

Line Item	Tag	Value	Unit	Period
Net income (loss)	`ProfitLoss`	$-4.72B	USD	3 Qtrs
Net income (loss)	`ProfitLoss`	$771.00M	USD	3 Qtrs
Net income (loss)	`ProfitLoss`	$-197.00M	USD	1 Quarter
Net income (loss)	`ProfitLoss`	$610.00M	USD	1 Quarter
Net change in operating assets and liabilities	`IncreaseDecreaseInOperatingCapital`	$1.72B	USD	3 Qtrs
Net change in operating assets and liabilities	`IncreaseDecreaseInOperatingCapital`	$1.52B	USD	3 Qtrs
Depreciation and amortization	`DepreciationAndAmortization`	$1.46B	USD	3 Qtrs
Depreciation and amortization	`DepreciationAndAmortization`	$1.58B	USD	3 Qtrs
Impairment of long-lived assets	`AssetImpairmentCharges`	$564.00M	USD	3 Qtrs
Impairment of long-lived assets	`AssetImpairmentCharges`	$1.50B	USD	3 Qtrs
Deferred income taxes, net and uncertain tax positions	`DeferredIncomeTaxesNetAndUncertainTaxPositions`	$-733.00M	USD	3 Qtrs
Deferred income taxes, net and uncertain tax positions	`DeferredIncomeTaxesNetAndUncertainTaxPositions`	$-650.00M	USD	3 Qtrs
Goodwill impairment	`GoodwillImpairmentLoss`	$6.10B	USD	3 Qtrs
Goodwill impairment	`GoodwillImpairmentLoss`	$300.00M	USD	3 Qtrs
Stock-based compensation	`ShareBasedCompensation`	$122.00M	USD	3 Qtrs
Stock-based compensation	`ShareBasedCompensation`	$106.00M	USD	3 Qtrs
Impairment of equity investment	`ImpairmentOfInvestments`	$103.00M	USD	3 Qtrs
Research and development in process	`ResearchAndDevelopmentExpense`	$175.00M	USD	3 Qtrs
Research and development in process	`ResearchAndDevelopmentExpense`	$54.00M	USD	3 Qtrs
Net gain from sale of long-lived assets and investments	`ProfitFromSaleOfLongLivedAssetsAndInvestment`	$53.00M	USD	3 Qtrs
Net gain from sale of long-lived assets and investments	`ProfitFromSaleOfLongLivedAssetsAndInvestment`	$48.00M	USD	3 Qtrs
Other items	`IncreaseDecreaseInOtherOperatingCapitalNet`	$-9.00M	USD	3 Qtrs
Other items	`IncreaseDecreaseInOtherOperatingCapitalNet`	$8.00M	USD	3 Qtrs
Venezuela impairment of net monetary assets	`VenezuelaImpairmentOfNetMonetaryAssets`	$45.00M	USD	3 Qtrs
Net cash provided by operating activities	`NetCashProvidedByUsedInOperatingActivities`	$1.37B	USD	3 Qtrs
Net cash provided by operating activities	`NetCashProvidedByUsedInOperatingActivities`	$2.08B	USD	3 Qtrs
Beneficial interest collected in exchange for securitized trade receivables	`CashFlowsBetweenTransferorAndTransfereeBeneficialInterest`	$1.37B	USD	3 Qtrs
Beneficial interest collected in exchange for securitized trade receivables	`CashFlowsBetweenTransferorAndTransfereeBeneficialInterest`	$962.00M	USD	3 Qtrs
Proceeds from sales of business, investments and long-lived assets	`ProceedsFromSaleAndMaturityOfMarketableSecurities`	$1.61B	USD	3 Qtrs
Proceeds from sales of business, investments and long-lived assets	`ProceedsFromSaleAndMaturityOfMarketableSecurities`	$880.00M	USD	3 Qtrs
Purchases of property, plant and equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	$607.00M	USD	3 Qtrs
Purchases of property, plant and equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	$438.00M	USD	3 Qtrs
Purchases of investments and other assets	`PaymentToAcquireMarketableSecuritiesAndOtherAssets`	$56.00M	USD	3 Qtrs
Purchases of investments and other assets	`PaymentToAcquireMarketableSecuritiesAndOtherAssets`	$194.00M	USD	3 Qtrs
Other investing activities	`PaymentsForProceedsFromOtherInvestingActivities`	$277.00M	USD	3 Qtrs
Other investing activities	`PaymentsForProceedsFromOtherInvestingActivities`	$-34.00M	USD	3 Qtrs
Acquisitions of subsidiaries, net of cash acquired	`PaymentsToAcquireBusinessesNetOfCashAcquired`	$-43.00M	USD	3 Qtrs
Net cash provided by investing activities	`NetCashProvidedByUsedInInvestingActivities`	$1.79B	USD	3 Qtrs
Net cash provided by investing activities	`NetCashProvidedByUsedInInvestingActivities`	$1.53B	USD	3 Qtrs
Repayment of senior notes and loans and other long-term liabilities	`RepaymentsOfLongTermDebt`	$1.00B	USD	3 Qtrs
Repayment of senior notes and loans and other long-term liabilities	`RepaymentsOfLongTermDebt`	$6.99B	USD	3 Qtrs
Proceeds from senior notes and loans, net of issuance costs	`ProceedsFromIssuanceOfLongTermDebt`	$4.43B	USD	3 Qtrs
Proceeds from senior notes and loans, net of issuance costs	`ProceedsFromIssuanceOfLongTermDebt`	$507.00M	USD	3 Qtrs
Net change in short-term debt	`ProceedsFromRepaymentsOfShortTermDebt`	$-1.63B	USD	3 Qtrs
Net change in short-term debt	`ProceedsFromRepaymentsOfShortTermDebt`	$-262.00M	USD	3 Qtrs
Other financing activities	`ProceedsFromPaymentsForOtherFinancingActivities`	$-69.00M	USD	3 Qtrs
Other financing activities	`ProceedsFromPaymentsForOtherFinancingActivities`	$-13.00M	USD	3 Qtrs
Dividends paid on ordinary shares	`PaymentsOfDividendsCommonStock`	$814.00M	USD	3 Qtrs
Dividends paid on ordinary shares	`PaymentsOfDividendsCommonStock`	$12.00M	USD	3 Qtrs
Dividends paid on preferred shares	`PaymentsOfDividendsPreferredStockAndPreferenceStock`	$195.00M	USD	3 Qtrs
Dividends paid on preferred shares	`PaymentsOfDividendsPreferredStockAndPreferenceStock`	$10.00M	USD	3 Qtrs
Dividends paid to non-controlling interests	`PaymentsOfDividendsMinorityInterest`	$38.00M	USD	3 Qtrs
Net cash used in financing activities	`NetCashProvidedByUsedInFinancingActivities`	$-2.85B	USD	3 Qtrs
Net cash used in financing activities	`NetCashProvidedByUsedInFinancingActivities`	$-3.24B	USD	3 Qtrs
Translation adjustment on cash and cash equivalents	`EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$-107.00M	USD	3 Qtrs
Translation adjustment on cash and cash equivalents	`EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$36.00M	USD	3 Qtrs
Net change in cash and cash equivalents	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect`	$-308.00M	USD	3 Qtrs
Net change in cash and cash equivalents	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect`	$912.00M	USD	3 Qtrs
Balance of cash and cash equivalents at beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$963.00M	USD	Point-in-time
Balance of cash and cash equivalents at beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$988.00M	USD	Point-in-time
Balance of cash and cash equivalents at beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$1.88B	USD	Point-in-time
Balance of cash and cash equivalents at beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$680.00M	USD	Point-in-time
Balance of cash and cash equivalents at end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$963.00M	USD	Point-in-time
Balance of cash and cash equivalents at end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$988.00M	USD	Point-in-time
Balance of cash and cash equivalents at end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$1.88B	USD	Point-in-time
Balance of cash and cash equivalents at end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$680.00M	USD	Point-in-time
Beneficial interest obtained in exchange for securitized trade receivables	`BeneficialInterestObtainedInExchangeForSecuritizedTradeReceivables`	$1.34B	USD	Point-in-time
Beneficial interest obtained in exchange for securitized trade receivables	`BeneficialInterestObtainedInExchangeForSecuritizedTradeReceivables`	$911.00M	USD	Point-in-time

Comprehensive Income 34 line items

Line Item	Tag	Value	Unit	Period
Net income (loss)	`ProfitLoss`	$-4.72B	USD	3 Qtrs
Net income (loss)	`ProfitLoss`	$771.00M	USD	3 Qtrs
Net income (loss)	`ProfitLoss`	$-197.00M	USD	1 Quarter
Net income (loss)	`ProfitLoss`	$610.00M	USD	1 Quarter
Currency translation adjustment	`OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax`	$264.00M	USD	1 Quarter
Currency translation adjustment	`OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax`	$-105.00M	USD	1 Quarter
Currency translation adjustment	`OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax`	$-577.00M	USD	3 Qtrs
Currency translation adjustment	`OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax`	$1.14B	USD	3 Qtrs
Unrealized gain (loss) from derivative financial instruments	`OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax`	$49.00M	USD	1 Quarter
Unrealized gain (loss) from derivative financial instruments	`OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax`	$118.00M	USD	3 Qtrs
Unrealized gain (loss) from derivative financial instruments	`OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax`	$-75.00M	USD	3 Qtrs
Unrealized gain (loss) from derivative financial instruments	`OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax`	$-19.00M	USD	1 Quarter
Unrealized gain (loss) from available-for-sale securities	`OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax`	$1.00M	USD	1 Quarter
Unrealized gain (loss) from available-for-sale securities	`OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax`	$20.00M	USD	3 Qtrs
Unrealized gain (loss) from available-for-sale securities	`OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax`	$-17.00M	USD	1 Quarter
Unrealized gain (loss) on defined benefit plans	`OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationNetOfTax`	$-12.00M	USD	3 Qtrs
Unrealized gain (loss) on defined benefit plans	`OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationNetOfTax`	$1.00M	USD	1 Quarter
Unrealized gain (loss) on defined benefit plans	`OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationNetOfTax`	$1.00M	USD	1 Quarter
Total other comprehensive income (loss)	`OtherComprehensiveIncomeLossNetOfTax`	$199.00M	USD	1 Quarter
Total other comprehensive income (loss)	`OtherComprehensiveIncomeLossNetOfTax`	$1.03B	USD	3 Qtrs
Total other comprehensive income (loss)	`OtherComprehensiveIncomeLossNetOfTax`	$-502.00M	USD	3 Qtrs
Total other comprehensive income (loss)	`OtherComprehensiveIncomeLossNetOfTax`	$-84.00M	USD	1 Quarter
Total comprehensive income (loss)	`ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest`	$269.00M	USD	3 Qtrs
Total comprehensive income (loss)	`ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest`	$-3.69B	USD	3 Qtrs
Total comprehensive income (loss)	`ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest`	$809.00M	USD	1 Quarter
Total comprehensive income (loss)	`ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest`	$-281.00M	USD	1 Quarter
Comprehensive income (loss) attributable to non-controlling interests	`ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest`	$75.00M	USD	3 Qtrs
Comprehensive income (loss) attributable to non-controlling interests	`ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest`	$11.00M	USD	1 Quarter
Comprehensive income (loss) attributable to non-controlling interests	`ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest`	$20.00M	USD	3 Qtrs
Comprehensive income (loss) attributable to non-controlling interests	`ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest`	$-26.00M	USD	1 Quarter
Comprehensive income (loss) attributable to Teva	`ComprehensiveIncomeNetOfTax`	$798.00M	USD	1 Quarter
Comprehensive income (loss) attributable to Teva	`ComprehensiveIncomeNetOfTax`	$-3.77B	USD	3 Qtrs
Comprehensive income (loss) attributable to Teva	`ComprehensiveIncomeNetOfTax`	$-255.00M	USD	1 Quarter
Comprehensive income (loss) attributable to Teva	`ComprehensiveIncomeNetOfTax`	$249.00M	USD	3 Qtrs

Data is extracted from SEC EDGAR XBRL filings. Values shown are as reported in the filing.